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Atrial fibrillation (AF) puts patients at risk of complications, including stroke. Warfarin therapy has been the mainstay
of antithrombotic treatment for reducing the risk of stroke in AF. However, warfarin has limitations that have motivated
development of several novel oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban.
Clinical trials demonstrate that the NOACs offer efficacy and safety that are equivalent to, or better than, those of
warfarin for reducing the risk of stroke in patients with nonvalvular AF. This review examines stroke risk reduction
in patients with AF from the perspective of the clinician balancing the risks and benefits of treatment options,
evaluates the most recent guidelines, and discusses 2 hypothetical patient cases to better illustrate how clinicians
may apply available data in the clinical setting. We reviewed guidelines for the reduction of stroke risk in AF and
data from clinical trials on the NOACs. Choosing antithrombotic treatment involves assessing the benefits of therapy
versus its risks. Risk indexes, including CHADS2, CHA2DS2-VASc, and HAS-BLED can help determine how to treat patients
with AF. Current guidelines suggest using these risk indexes to customize treatment to individual patients. Many current
treatment guidelines also incorporate recommendations for the use of NOACs as an alternative to warfarin. As
additional data emerge and guidelines are updated, these recommendations will likely evolve. In the interim,
clinicians may consider published guidelines and clinical trial results on NOACs. Real-world experience will provide
clinicians with additional insight into their treatment decisions.
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Successful healthcare interventions improve patient out-
comes and reduce costs associated with disease manage-
ment. Guidelines provide a standardized, evidence-based
approach to the diagnosis and treatment of disease, with
a goal of optimizing health outcomes. When available,
preventive measures to reduce the risk of disease compli-
cations are an important element of treatment. Atrial
fibrillation (AF), which affected an estimated 5.2 million
adults in the United States in 2010, is a disease state in
which patients are at risk of complications, including
stroke [1]. AF is a highly prevalent cardiac arrhythmia that* Correspondence: anamin@uci.edu
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unless otherwise stated.imparts a 2- to 7-times greater risk of embolic or transient
stroke [2, 3]. AF-related stroke is more severe than stroke
without AF, and is associated with greater disability and
subsequent medical needs [4, 5]. The high AF-related
morbidity is reflected in a substantial economic burden.
For 2010, the projected incremental cost of AF in the
United States ranged from $6.0 billion to $26.0 billion [6].
Antithrombotic therapy can reduce the risk of stroke in
patients with AF [7–11]; however, many at-risk patients
are untreated or undertreated [12–15]. Antithrombotic
treatment for stroke risk reduction in patients with AF has
traditionally focused on anticoagulation with a vitamin K
antagonist (VKA), primarily warfarin [2]. Warfarin is
highly effective for reducing the risk of stroke. However,
warfarin has a narrow therapeutic window and many pa-
tients have difficulty remaining within the therapeuticn Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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over-anticoagulation may result in bleeding. Warfarin can
be challenging to use in the clinical setting due to dietary
and drug interactions, and variability in dose response due
to genetic and environmental factors [13]. Warfarin neces-
sitates regular monitoring and dose adjustments to enable
individual patients to receive safe and effective treatment
[13, 16]. Many physicians overestimate bleeding risk and
underestimate the benefit of stroke prevention [17]. Bleed-
ing risk and concerns about bleeding risk, as well as other
clinical features of warfarin, may lead clinicians to rule
it out as a treatment option; hence, many patients re-
main untreated [18–20]. Until recently, aspirin was the
only treatment alternative for patients unsuitable for
VKA therapy. Although bleeding risk is lower and ad-
ministration is simpler with aspirin, the efficacy of as-
pirin in stroke prevention is inferior to that of warfarin
[8, 21]. Thus, the conventional treatment options of
warfarin and aspirin have left a segment of the patient
population untreated and/or undertreated and at in-
creased risk of stroke [22].
The limitations of the traditional options for stroke
prevention in patients with AF have motivated the devel-
opment of several novel oral anticoagulants (NOACs).
Recent clinical trials have found that the NOACs offer
efficacy and safety equivalent to, or better than, those
of warfarin for reducing the risk of stroke in patients
with nonvalvular AF (NVAF) [23–26]. As more clinical
experience is gained with the NOACs, changes in treat-
ment paradigms and guidelines will undoubtedly ensue.
This review examines stroke prevention in patients with AF
from the perspective of the clinician trying to balance the
risks and benefits of treatment options. Use of treatment
guidelines and the application of findings from recent clin-
ical trials will help facilitate high-quality and cost-effective
medical care; however, effective care must be tailored to the
individual patient. In addition to reviewing the most recent
guidelines for stroke prevention in AF, we will discuss 2
hypothetical patient cases to better understand how cli-
nicians may apply these measures and the available data
in the clinical setting.
Stroke risk reduction in NVAF with NOACs
Several NOACs are available in the United States for re-
ducing the risk of stroke in patients with NVAF, includ-
ing the direct thrombin inhibitor dabigatran and the
factor Xa inhibitors rivaroxaban, apixaban and edoxaban
[26–30]. A brief summary of the results of key phase 3
clinical trials comparing the NOACs with either warfarin
or aspirin for reducing the risk of stroke in NVAF is pro-
vided in Table 1 [23–26, 31, 32]. These results provide
support for the integration of NOACs into treatment
paradigms for stroke risk reduction in AF as potential
first-line options.Guidelines and quality measures for stroke risk reduction
in AF
Several guidelines discuss stroke risk reduction in patients
with AF (Table 2), including recommendations from the
American College of Cardiology (ACC), the American
College of Chest Physicians (ACCP), the American Heart
Association (AHA), the American Stroke Association
(ASA), the Heart Rhythm Society (HRS), the European So-
ciety of Cardiology (ESC), and the American Academy of
Neurology (AAN) [7–11]. In general, treatment decisions
are based on an assessment of the individual patient’s
stroke risk, with a concurrent assessment of bleeding risk
and other patient-related factors, such as his or her ability
to adhere to monitoring requirements and personal pref-
erences [7, 10]. However, specific recommendations vary
as to how to assess these risks, when to treat with anti-
thrombotic therapy, and which treatments to use.
The CHADS2 and CHA2DS2-VASc risk indexes predict
the risk of stroke in patients with AF. Both the ACC/AHA/
HRS guidelines and the ESC guidelines mention the ATRIA
and HEMORR2 HAGES scores for bleeding risk, but
acknowledge that the HAS-BLED risk index is most
predictive of bleeding events. Together, these scoring
systems can be used to evaluate an approach to treat-
ment in patients with AF. The CHADS2 score is based
on a patient’s history of Congestive heart failure (1 point),
Hypertension (1 point), Age ≥75 years (1 point), Diabetes
(1 point), and history of Stroke or transient ischemic attack
(TIA, 2 points; Table 3) [33]. Scores of 0, 1, or ≥2 indicate
low, moderate, or high stroke risk, respectively [8, 34]. The
CHADS2 risk scoring index has been thoroughly validated
[33–35]; is simple, inexpensive, and broadly applicable; and
most importantly, it allows identification of patients at low
risk of stroke who may not receive significant benefit from
anticoagulant therapy. However, the CHADS2 risk score
has limitations, primarily that patients deemed at low risk
with CHADS2 still have a stroke risk of 2.2 % per year, in
addition, there is a lack of differentiation between stroke
risk factors and risk factors that do not consistently predict
stroke (i.e., congestive heart failure). As a result, some pa-
tients may be identified as moderate- rather than low-risk
stroke candidates, or vice versa [33–35]. Also, in keeping
the CHADS2 risk score simple, some common stroke risk
factors are not included [35, 36].
The ACC/AHA/HRS and ESC advocate using the
CHA2DS2-VASc score instead of the CHADS2 score to
assess stroke risk. The ESC states that the CHA2DS2-VASc
score more accurately identifies “truly low-risk” patients
with AF who are not likely to benefit from oral anti-
coagulant therapy (Table 3) and, conversely, those patients
who may benefit from anticoagulation because they are at
risk for stroke or systemic thromboembolism [7]. The
CHA2DS2-VASc score has been shown to identify some
patients considered low risk by CHADS2 (score of 0) to
Table 1 Phase 3 clinical trials of NOACs: study design and outcomes
Trial name Trial design No. of patients Outcomes (annual rate vs. comparator,a %/y)




PROBE designd N = 18113 Dabigatran
150 mg bid: n = 6076
Dabigatran 150 mg: RR 0.66 (95 % CI 0.53,
0.82; p < 0.001 for superiority)
Dabigatran 150 mg: RR
0.88 (95 % CI 0.77, 1.00;
p = 0.051)
Major bleeding: Dabigatran
150 mg: RR 0.93 (95 % CI 0.81,
1.07; p = 0.31)
Dabigatran 150 mg: RR
0.40 (95 % CI 0.27, 0.60;
p < 0.001)
Dabigatran 110 mg
bid: n = 6015
Dabigatran 110 mg: RR 0.91 (95 % CI 0.74,
1.11; p < 0.001 for noninferiority)
Dabigatran 110 mg: RR
0.91 (95 % CI 0.80, 1.03;
p = 0.13)
Dabigatran 110 mg: RR 0.80
(95 % CI 0.69, 0.93; p = 0.003)
Dabigatran 110 mg: RR
0.31 (95 % CI 0.20, 0.47;
p < 0.001)
Warfarin (adjusted











HR 0.85 (95 % CI 0.70,
1.02; p = 0.07)
Major and CRNM bleeding:
HR 1.03 (95 % CI 0.96, 1.11;
p = 0.44)
HR 0.67 (95 % CI 0.47,
0.93; p = 0.02)
Warfarin (adjusted
dose, target INR 2.0–
3.0): n= 7133
HR 0.88 (95 % CI 0.75, 1.03; p < 0.001 for
noninferiority; p = 0.12 for superiority)e
Major bleeding: HR 1.04 (95 %







N = 21105 Edoxaban
60 mg once daily:
n = 7035
Edoxaban 60 mg: HR 0.79 (97.5 % CI 0.63,
0.99; p < 0.001 for noninferiority; p = 0.08
for superiority)f
Edoxaban 60 mg: HR,
0.92 (95 % CI. 0.83, 1.01;
p = 0.08)
Major bleeding: Edoxaban
60 mg: HR 0.80 (95 % CI 0.71,
0.91; p < 0.001)
Edoxaban 60 mg: HR
0.47 (95 % CI 0.34, 0.63;
p < 0.001)
Edoxaban 30 mg
once daily: n = 7034
Edoxaban 30 mg: HR 1.07 (97.5 % CI 0.87,
1.31; p = 0.005 for noninferiority; p = 0.10
for superiority)f
Edoxaban 30 mg: HR,
0.87 (95 % CI, 0.79, 0.96;
p = 0.006)
Edoxaban 30 mg: HR 0.47
(95 % CI 0.41, 0.55; p < 0.001)
Edoxaban 30 mg: HR










N = 18201 Apixaban
5 mg bid: n = 9120
HR 0.79 (95 % CI 0.66, 0.95; p < 0.001 for
noninferiority; p = 0.01 for superiority)
HR 0.89 (95 % CI 0.80,
0.998; p = 0.047)
Major bleeding: HR 0.69
(95 % CI 0.60, 0.80; p < 0.001)
HR, 0.42 (95 % CI, 0.30,
0.58; p < 0.001)
Warfarin (adjusted
dose, target INR






N = 5599 Apixaban
5 mg bid: n = 2808
HR 0.45 (95 % CI 0.32, 0.62; p < 0.001) HR 0.79 (95 % CI 0.62,
1.02; p = 0.07)
Major bleeding: HR 1.13
(95 % CI 0.74, 1.75; p = 0.57)
HR 0.85 (95 % CI 0.38,
1.90; p = 0.69)
Aspirin 81–324 mg/d:
n = 279
bid twice daily, CI confidence interval, CRNM clinically relevant nonmajor, HR hazard ratio, INR international normalized ratio, ITT intention-to-treat, NOAC novel oral anticoagulant, PROBE prospective, randomized, open,
blinded end-point, RR relative risk
aNOACs were compared with warfarin in the RE-LY, ROCKET-AF, ENGAGE AF-TIMI 48 and ARISTOTLE trials and with aspirin in the AVERROES trial
bp values are for superiority
cValues for RE-LY are given as RR
dPROBE design
eITT population
fModified ITT (mITT) population















Table 2 Guidelines for the management of stroke in NVAF
2012 AHA/ASA: Scientific Advisory [8] 2012 ACCP [11] 2012 ESC [7] 2014 AAN [9]a 2014 ACC/AHA/HRS [10]
Stroke risk Guideline recommendations by stroke risk
Low CHADS2 = 0 CHADS2 = 0 CHA2DS2-VASc = 0 Clinicians might not offer
anticoagulation to patients with
NVAF who lack additional risk
factors
CHA2DS2-VASc = 0
Aspirin, based on patient preference,
estimated bleeding risk if
anticoagulated, and access to high-
quality anticoagulation monitoring





antithrombotic therapy with aspirin
or no therapy at all
Reasonable to omit antithrombotic
therapy
If antithrombotic therapy chosen,
aspirin (75–325 mg/d) suggested
rather than OAC or aspirin plus
clopidogrelb
Moderate CHADS2 = 1 CHADS2 = 1 CHA2DS2-VASc = 1 Not discussed CHA2DS2-VASc = 1
Aspirin, based on patient
preference, estimated bleeding risk
if anticoagulated, and access to
high-quality anticoagulation moni-
toring or adjusted-dose warfarin in
appropriate patients
OAC suggested rather than no
therapy. OAC suggested rather
than aspirin alone or aspirin plus
clopidogrel.b If OAC unsuitable or
not desired, aspirin plus
clopidogrelb suggested rather than
aspirin alone
OAC therapy with adjusted-dose
VKA (INR 2.0–3.0); a direct thrombin
inhibitor (dabigatran); an oral factor
Xa inhibitor (e.g., rivaroxaban, apixa-
ban) should be considered, based
upon an assessment of the risk of
bleeding complications and patient
preferences. For female patients
aged <65 years with lone AF
(CHA2DS2-VASc = 1 due to sex), no
antithrombotic therapy should be
considered
No therapy or OAC or aspirin may
be considered
High CHADS2≥2 CHADS2≥2 CHA2DS2-VASc ≥2 CHA2DS2-VASc ≥2
Adjusted-dose warfarin in
appropriate patients (in patients
unsuitable for warfarin, aspirin plus
clopidogrelb offers more protection
against stroke than aspirin but with
an increased risk of major bleeding)
OAC suggested rather than no
therapy, aspirin alone, or aspirin
plus clopidogrel.b If OAC
unsuitable or not desired, aspirin
plus clopidogrelb suggested rather
than aspirin alone
OAC therapy with adjusted-dose
VKA (INR 2.0–3.0); a direct thrombin
inhibitor (dabigatran); an oral factor
Xa inhibitor (e.g., rivaroxaban, apix-
aban) recommended, unless
contraindicated
Clinicians should routinely offer
anticoagulation to patients with






Guideline recommendations by agent
Adjusted-
dose VKA
See recommendations by CHADS2
score
Patients with AF and mitral
stenosis
INR of 2.0–3.0 likely reduces
frequency and severity of ischemic
stroke vs lower INR levels
Patients with mechanical heart
valve (target INR 2.0–3.0 or 2.5–3.5
based on type and location of
prosthesis)
Patients with AF and stable CAD Patients with NVAF and
CHAD2DS2-VASc ≥2 with end-
















Table 2 Guidelines for the management of stroke in NVAF (Continued)
Patients with AF and ACS not
undergoing stent placement (in
combination with single
antiplatelet for first 1–12 mo, after
which treat as for patients with AF
and stable CAD)
Dabigatran 150 mg bid is an efficacious
alternative to warfarin in patients
with NVAF who have ≥1 additional
risk factor for stroke and CrCl
>30 mL/min
Recommended over adjusted-dose
VKA in cases where OAC
recommended
Probably more effective than
warfarin for reducing risk of stroke
or SE
Recommended for patients unable
to maintain a therapeutic INR level
with warfarin
Reduce dosage to 75 mg bid in
patients with moderate renal
impairment (CrCl 15–30 mL/min)c
Dabigatran 150 mg bid
recommended for most patients
Hemorrhage risk was similar overall
between dabigatran 150 mg and
warfarin; ICH was less frequent with
dabigatran 150 mg than warfarin;
GI bleeding more frequent with
dabigatran 150 mg than with
warfarin
May be considered in patients
with renal impairment: 150 mg bid
in patients with mild renal
impairment (CrCl >30 mL/min);
150 mg or 75 mg bid in patients
with moderate renal impairment
(CrCl >30 mL/min); 75 mg bid in
patients with severe renal
impairment (CrCl 15–30 mL/min)
• Dabigatran 110 mg bid
recommended for:
• Elderly patients (aged ≥80 y)
• Concomitant use of interacting
drugs
• HAS-BLED ≥3
• Moderate renal impairment (CrCl
30–49 mL/min)
Not recommended in patients with
severe renal impairment (CrCl
<15 mL/min)
Recommended over adjusted-dose
VKA in cases where OAC
recommended
Not recommended in patients
with severe renal impairment
(CrCl <30 mL/min)
Not recommended for patients
with CrCl<15 mL/min
Rivaroxaband 20 mg/d is a reasonable alternative
to warfarin in patients with NVAF at
moderate to high risk of stroke
(prior history of TIA, stroke, or SE, or
≥2 additional risk factors) 15 mg/d
may be considered in patients with
renal impairment (CrCl 15–50 mL/
min)c
Recommended over adjusted-dose
VKA in cases where OAC
recommended
In patients with NVAF at high risk
of cerebral or systemic embolism.
Probably as effective as warfarin for
prevention of cerebral and systemic
embolism, with no difference in risk
of major bleeding episodes except
GI bleeding
Recommended for patients unable
to maintain a therapeutic INR level
with warfarin
May be considered in patients
with renal impairment: 20 mg/d
for patients with mild renal
impairment (CrCl >50 mL/min);
15 mg/d for patients with moderate
or severe renal impairment (CrCl
15–50 mL/min)
Rivaroxaban 20 mg/d




• Moderate renal impairment (CrCl
30–49 mL/min)
Should not be used in patients
with severe renal impairment
(CrCl <15 mL/min)
Not approved at time of guideline
preparation
Not recommended in patients with
severe renal impairment (CrCl
<30 mL/min)
Associated with lesser frequency of
ICH and fatal bleeding compared
with warfarin
Not recommended for patients
with CrCl < 15 mL/min
Apixabane As an alternative to warfarin or
aspirin: 5 mg bid is relatively safe and
efficacious in patients with NVAF who
have ≥1 additional risk factor and ≤1
of the following additional criteria:
Recommended over adjusted-dose
VKA in cases where OAC recom-
mended apixaban 5 mg bid
In patients with NVAF at moderate
risk of embolism, 5 mg bid is likely
more effective than warfarin
Recommended for patients unable
















Table 2 Guidelines for the management of stroke in NVAF (Continued)
age ≥80 y, weight ≤60 kg, or serum
creatinine ≥1.5 mg/dL
• 2.5 mg bid may be considered in
patients with ≥2 of the additional
criteria described abovec
Apixaban 2.5 mg bid recommended
for patients with renal impairment
Superiority is related to decreased
risk of bleeding and reduced
mortality, while its effect on
reduction in risk of cerebral and
systemic embolism is not superior
to warfarin
5.0 mg bid in patients with mild
or moderate renal impairment or
2.5 mg bid in patients who meet
dose reduction criteria (CrCl
≥1.5 mg/dL, ≥80 years of age,
body weight ≤60 kg)
Should not be used in patients
with severe renal impairment
(CrCl <25 mL/min)
Not approved at time of guideline
preparation
Not recommended in patients
with severe renal impairment
(CrCl <30 mL/min)
Likely more effective than aspirin
for decreasing risk of stroke or SE
in patients with NVAF who have
moderate risk of embolism and are
not candidates for warfarin
No recommendation in patients
with severe renal impairment or
end-stage CKD
Edoxaban Not approved at time of guideline
preparation
Not approved at time of guideline
preparation
Not approved at time of guideline
preparation
Not approved at time of guideline
preparation




Oral anticoagulation is likely more
effective than clopidogrel plus
aspirin, but ICH is more common
Triflusal plus acenocoumarol and
moderate-intensity anticoagulation
(INR 1.25–2.0) is likely more effective
than treatment with acenocoumarol
alone and conventional-intensity
anticoagulation
Combination of low-dose aspirin
and dose-adjusted VKA therapy
probably increases risk of
hemorrhage
Combination of clopidogrel and
aspirin reduces risk of major
vascular events but increases risk
of major hemorrhage compared
with aspirin alone
AAN American Academy of Neurology, ACC American College of Cardiology, ACCP American College of Chest Physicians, ACS acute coronary syndrome, AF atrial fibrillation, AHA American Heart Association, ASA
American Stroke Association, bid twice daily, CAD coronary artery disease, CHADS2 Congestive heart failure, Hypertension, Age ≥65 y, Diabetes, Stroke or transient ischemic attack (doubled), CHA2DS2-VASc Congestive
heart failure, Hypertension, Age ≥75 y (doubled), Diabetes, Stroke or transient ischemic attack (doubled), Vascular disease, Age 65–74 y, Sex category (female), CKD chronic kidney disease, CrCl creatinine clearance, ESC
European Society of Cardiology, GI gastrointestinal, HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly, HRS Heart Rhythm
Society, ICH intracranial hemorrhage, INR international normalized ratio, NVAF nonvalvular atrial fibrillation, OAC oral anticoagulant, SE systemic embolism, TIA transient ischemic attack, VKA vitamin K antagonist
aAAN recommends that clinicians use risk stratification tools to help determine stroke risk in patients with NVAF, but cautions physicians not to rigidly interpret anticoagulation thresholds suggested by these tools and
does not stratify recommendations using a scoring system
bIn the United States, clopidogrel and the more recently developed antiplatelet agents, prasugrel and ticagrelor, are used in patients with ACS, but none are indicated for stroke prevention in AF
cRecommendations made; however, safety and efficacy have not been established
dRivaroxaban should be administered once daily with the evening meal















Table 3 Stroke risk scoring systems: CHADS2 and CHA2DS2-VASc
CHADS2 score
Scoring system Stroke rates associated with CHADS2
score
Risk factor Points Risk
score
Adjusted stroke rate
(%/y)a, b (95 % CI)
Risk of
stroke
C CHF 1 0 1.9 (1.2, 3.0) Low
H Hypertension 1 1 2.8 (2.0, 3.8) Moderate
A Age ≥75 y 1 2 4.0 (3.1, 5.1)
D Diabetes 1 3 5.9 (4.6, 7.3)
S2 Prior stroke/TIA 2 4 8.5 (6.3, 11.1) High
5 12.5 (8.2, 17.5)
6 18.2 (10.5, 27.4)
CHA2DS2-VASc score
Scoring system Stroke rates associated with CHA2DSs-
VASc score
Risk factor Points Risk
score
TE rate during 1 year





1 0 0 Low
H Hypertension 1 1 0.6 (0.0, 3.4) Moderate
A2 Age ≥75 y 2 2 1.6 (0.3, 4.7)
D Diabetes 1 3 3.9 (1.7, 7.6) High
S2 Prior stroke/TIA/
TE
2 4 1.9 (0.5, 4.9)
V Vascular disease
(prior MI, PAD, or
aortic plaque)
1 5 3.2 (0.7, 9.0)
A Age 65–74 y 1 6 3.6 (0.4, 12.3)
Sc Sex category
(female sex)
1 7 8.0 (1.0, 26.0)
CHF congestive heart failure, CI confidence interval, LV left ventricular,
MI myocardial infarction, PAD peripheral artery disease, TE thromboembolism,
TIA transient ischemic attack
aAdapted from Gage BF et al. JAMA. 2001;285:2864–70 [33]
bAdjusted stroke is expected stroke rate per 100 person-years from exponential
survival model, assuming no aspirin was taken
cAdapted from Lip GYH et al. Chest. 2010;137:263–72 [34]
dp value for trend = 0.003
Table 4 Bleeding risk scoring system: HAS-BLED. Adapted from
Pisters R et al. Chest. 2010;138;1093–100 [42]
Risk factor Points
H Hypertension 1





L Labile INRs 1
E Elderly (age >65 y) 1
D Drugs or alcohol (1 point each) 1 or 2







INR international normalized ratio
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CHA2DS2-VASc considers additional risk factors, including
Vascular disease (1 point) and Sex category (1 score point
for female sex), and heightens the risk rendered by older
age, assigning 2 points rather than 1 (as with CHADS2) for
age ≥75 years, as well as 1 point for the risk factor of age
65–74 years [34]. With CHA2DS2-VASc, patients with
scores of 0, 1, or ≥2 are considered to be at low, moderate,
or high risk of stroke, respectively [34]. In one study of the
predictive value of risk classification schemes, when pa-
tients were categorized by CHA2DS2-VASc score, 0 % of
low-risk patients, 0.6 % of moderate-risk patients, and 3 %
of high-risk patients experienced a thromboembolic event.
In contrast, when the same cohort of patients was classified
according to the CHADS2 scoring system, 1.4 % of low-risk, 1.9 % of moderate-risk, and 3.1 % of high-risk patients
experienced an event [34]. Despite these potential advan-
tages, the CHA2DS2-VASc score index lacks the extensive
validation that CHADS2 has received, and studies have
demonstrated a similar predictive ability for the 2 indexes
[11, 34, 40].
The AAN guidelines explicitly acknowledge the discrep-
ancies between the risk scoring systems, stating “although
multiple risk stratification tools are available for estimating
the absolute stroke risk of patients with NVAF, the absolute
stroke risks estimated by these tools vary widely [9].” Rather
than a score-based recommendation, the AAN acknowl-
edges that determining when the benefit of reducing stroke
risk will outweigh the harm of increased bleeding risk is dif-
ficult, and emphasizes the importance of patient preference
and physician judgment under these circumstances [9].
Concurrent assessment of stroke and bleeding risk
presents a clinical challenge, as many of the risk factors
for stroke and bleeding overlap [11]. Indeed, a subgroup
analysis of the RE-LY trial demonstrated an increased risk
for bleeding associated with higher CHADS2 scores in
patients receiving oral anticoagulation [41]. Among the
bleeding risk scores available, HAS-BLED has been in-
dependently validated, and correlates well with intra-
cranial hemorrhage risk (Table 4) [7, 42]. HAS-BLED
includes the following risk factors: Hypertension, Abnormal
renal/liver function, Stroke, Bleeding history or predis-
position, Labile international normalized ratio (INR),
Elderly (age ≥65 years), and Drugs (concomitant antiplate-
let/nonsteroidal anti-inflammatory drug or alcohol) [7, 11].
While the ESC suggests using the HAS-BLED bleeding risk
Amin and Deitelzweig Thrombosis Journal  (2015) 13:29 Page 8 of 15score [7], the ACC/AHA/HRS, ASA, and ACCP do not
endorse a specific scoring system, but do advise that an
assessment of bleeding risk is needed [8, 11, 41]. The
ESC guidelines recommend caution along with efforts
to correct potentially reversible bleeding risk factors when
prescribing antithrombotic therapy for patients with a
HAS-BLED score ≥3. Importantly, the ESC guidelines
emphasize that: whereas the HAS-BLED score should be
used to identify modifiable bleeding risks, a high HAS-
BLED score alone should not exclude patients from oral
anticoagulant treatment [7].
NOACs have been included in the most recent up-
dates to guidelines for stroke prevention in patients with
AF (Table 2) [7–11]. It should be noted that edoxaban
has not been included in the guideline recommendations
because it was not approved at the time of publication.
The ESC recommends the NOACs over warfarin based
on their better efficacy, safety, and convenience [7], whereas
the AHA/ASA recommend the NOACs as an alternative to
warfarin in the presence of at least 1 additional risk factor
for stroke [8]; neither guideline recommends one NOAC
over another. While the ACC/AHA/HRS recommend any
of the 3 NOACs (i.e., dabigatran, rivaroxaban, or apixaban)
as an efficacious alternative to warfarin [10], the ACCP
guidelines recommend dabigatran 150 mg twice daily
in place of adjusted-dose VKA [11]. (The ACCP guidelines
include dabigatran but not apixaban or rivaroxaban in their
recommendations, as the latter 2 NOACs were not yet ap-
proved when the guidelines were drafted [11].) The ACCP
guidelines favor oral anticoagulants over aspirin alone or,
for patients at intermediate to high risk of stroke for whom
warfarin is unsuitable, suggest aspirin given with clopido-
grel; where oral anticoagulation is indicated, dabigatran is
recommended over warfarin [11]. The AAN guideline up-
date offers recommendations for specific NOACs in lieu of
or as an alternative to warfarin based on type of stroke risk
(i.e., general risk [dabigatran 150 mg], high risk of cerebral
or systemic embolism [SE] [rivaroxaban], moderate risk of
embolism [apixaban 5 mg twice daily]) [9]. Additionally,
the AAN update recommends apixaban 5 mg bid over
aspirin for reducing risk of stroke or SE [9], and the
AAN guidelines include a recommendation for the addition
of clopidogrel to aspirin as an alternative for patients
with AF in whom warfarin is considered unsuitable [9].
It should be noted that while the ACC, ACCP, AHA,
ASA, HRS, and ESC use the CHADS2, CHA2DS2-VASc,
and/or HAS-BLED risk scores to determine their treat-
ment recommendations, these risk scoring systems are
based on the results of trials during the era in which
patients were receiving warfarin, aspirin, or placebo,
and not the new NOACs [10, 43–45]. The study that
validated the CHADS2 score measured stroke risk
among patients who were not receiving any form of
anticoagulant therapy [33].Performance and quality measures from the Joint
Commission, a US healthcare accrediting organization
formerly known as the Joint Commission on Accreditation
of Healthcare Organizations, and from the ACC/AHA also
provide guidance on the treatment of patients with NVAF
[46, 47]. Published in 2008, the Joint Commission’s Stroke
Performance Implementation Guide recommends warfarin
(unless contraindicated) for patients with AF-related stroke
[47]. ACC/AHA performance measures, also published
in 2008, recommend antithrombotic therapy with aspirin
or warfarin for patients with NVAF based on the patient’s
stroke risk category [46].
More recently, the Stroke and Stroke Rehabilitation
Work Group provided guidance in 2012 with quality
measures to improve outcomes in stroke, TIA, and stroke
rehabilitation. Composed of the AAN, American College
of Radiology, National Committee for Quality Assurance,
and the American Medical Association–convened Phys-
ician Consortium for Performance Improvement® (PCPI®),
the Stroke and Stroke Rehabilitation Work Group advo-
cates anticoagulant therapy with dabigatran, rivaroxaban,
warfarin, or low-molecular-weight heparin at discharge for
patients with AF [48].
Application of treatment guidelines to clinical practice
With multiple oral anticoagulants now available to reduce
the risk of stroke in patients with NVAF, guidelines and
treatment paradigms will continue to evolve to reflect find-
ings from clinical trials and emerging clinical experience.
The hypothetical cases that follow explore how clinicians
might apply guidelines and clinical trial data to treat-
ment decisions for the patient throughout the clinical
course of NVAF.
Hypothetical patient case 1: Balancing the benefit of
thromboprophylaxis with the risk of bleeding
BL is a 64-year-old white woman who presents to the
emergency room with cellulitis of the left forearm that
has not responded to outpatient antibiotic treatment. BL
takes metoprolol for hypertension, but no other medica-
tions. She has no history of diabetes. She is a nonsmoker
who exercises regularly and occasionally has a glass of
wine with dinner. Physical examination reveals the fol-
lowing: body mass index (BMI), 22 kg/m2 (height, 5′7′′;
weight, 139 lbs); blood pressure, 144/82 mm Hg; pulse,
78 bpm, irregular; temperature, 101 °F. On electrocardio-
gram (ECG), an irregularly irregular rhythm is noted with
no ST-elevation and a normal axis. Apart from moderate
cellulitis of the left forearm and associated signs of infec-
tion, no other abnormal findings are noted during the
physical examination.
BL is admitted to the hospital and the cellulitis responds
to intravenous antibiotics. She asks if her irregular heart
rhythm will require additional treatment or a repeat of
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inquiry, her hospitalist notes that 2 years ago BL had been
examined for complaints of breathlessness and a rapid
heart rate. After a complete cardiac workup at that time,
she had been diagnosed with paroxysmal NVAF and was
prescribed warfarin. BL states she didn’t like the frequent
blood tests that were associated with warfarin and often
found it difficult to get to the anticoagulant clinic due to
her work schedule. During a follow-up visit approximately
2 months after BL had started taking warfarin, her phys-
ician found that she was still in AF, although her heart rate
had returned to normal, and although he recommended
that she continue taking warfarin, she chose to stop it at
that time.
Case discussion
Due to her history of hypertension, BL has a HAS-BLED
score of 1, a CHADS2 score of 1, and a CHA2DS2-VASc
score of 2. Her HAS-BLED score indicates a low risk of
bleeding. Her CHADS2 score indicates a moderate risk of
stroke, which is associated with a stroke rate of 2.8 % per
year [33]. In contrast, her CHA2DS2-VASc score places
her in the high-risk category, although the rate of stroke
associated with a CHA2DS2-VASc score of 2 is 2.2 % per
year, similar to that associated with her CHADS2 score
[10]. Her moderate to high stroke risk (depending on the
scoring system used) suggests the importance of stroke
prevention in this patient.
Treatment guidelines provide various recommendations
for patients with a CHADS2 score of 1 (or a CHA2DS2-
VASc score of ≥2), ranging from daily aspirin to oral anti-
coagulation with warfarin or a NOAC (Table 2) [7–11]. In
the present case, however, an effective treatment choice for
BL must also consider her low risk of bleeding and her past
noncompliance with warfarin therapy. Based on BL’s history
of difficulty maintaining a therapeutic INR while on war-
farin and adhering to monitoring requirements, warfarin
would not be the ideal first choice for this patient. Instead,
one of the NOACs may provide a safe, efficacious, and con-
venient alternative.
Consideration of pharmacologic properties and patient-
specific characteristics, such as comorbidities, may help in
the identification of a specific NOAC for stroke preven-
tion (Table 5) [23–31, 49–58]. However, in this case, BL’s
medical history and concomitant medication (metoprolol)
do not rule out any of the NOACs. Given a CHADS2 score
of 1, one might consider aspirin versus a NOAC. In
contrast, her CHA2DS2-VASc score of 2 would suggest
that an anticoagulant is a more appropriate choice. As
noted previously, aspirin is less effective than warfarin in
preventing stroke in patients with NVAF [21]. Of the
NOACs, only apixaban has been studied head-to-head
versus aspirin (AVERROES trial) [32]. The AVERROES
trial demonstrated greater efficacy with apixaban insignificantly reducing the risk of stroke and SE compared
with aspirin (hazard ratio 0.45; 95 % confidence interval,
0.32, 0.62; p < 0.001; Table 1) [32]. For example, the annual
rate of stroke or SE was 1.6 % (51/2808) with apixaban
versus 3.7 % (113/2791) with aspirin, with no significant
difference between treatments in rates of major (p = 0.57),
gastrointestinal (GI; p = 0.71), or intracranial (p = 0.69)
bleeding [31]. Based on the results of the AVERROES trial,
and given the low risk of bleeding anticipated for BL based
on her HAS-BLED score of 1, using an oral anticoagulant
instead of aspirin on balance appears to be the better
choice, considering that complications of stroke can be
life-debilitating.
Hypothetical patient case 2: Identifying and managing
stroke risk in the midst of comorbidities and a high risk
of bleeding
AS is a 73-year-old black man with type 2 diabetes,
hypertension, and persistent NVAF who presents to the
emergency room with complaints of occasional palpita-
tions, lightheadedness, and a productive cough. He takes
metformin for diabetes, valsartan with chlorthalidone for
hypertension, and a daily aspirin tablet for his AF. He is
a nonsmoker and leads a generally sedentary lifestyle.
On physical examination, AS has a BMI of 34 kg/m2
(height 5′10′′; weight, 237 lbs); blood pressure, 154/90 mm
Hg; pulse, 100 bpm; and temperature, 102 °F. His lab
and test results were consistent with a diagnosis of acute
pneumonia.
AS is admitted to the hospital and treated for pneu-
monia. Past history reveals that he was diagnosed 2 years
ago with AF and treated at that time with warfarin,
which was stopped 1 year ago due to a GI bleed. Subse-
quently, he was put on an aspirin regimen of 75 mg per
day. During the current visit AS expresses concern to
the hospitalist about his persistent AF, diabetes, and
high blood pressure, all of which increase his risk of
stroke. He says he wants to resume oral anticoagulant
treatment, which he thinks may be better for him than
aspirin.
Case discussion
This patient’s age and history of hypertension and diabetes
give him a CHADS2 score of 2 (and CHA2DS2-VASc score
of 3), which indicates an increased risk of stroke and is as-
sociated with a stroke rate of 4.0 % per year based on his
CHADS2 score, or 3.2 % per year based on his CHA2DS2-
VASc score [10, 33]. His age (≥65 years), past history of GI
bleeding, and hypertension add up to a HAS-BLED score
of 3, which is linked to an increased risk of bleeding, and
data show it to be associated with a bleeding rate of
3.74 % per year [42]. The high risk of both stroke and
bleeding call for immediate stroke prevention. Guideline
recommendations for patients with a CHADS2 score of 2
Table 5 Clinical and pharmacologic properties of apixaban, rivaroxaban, dabigatran, and edoxaban
Criteria Dabigatran [28] Rivaroxaban [30] Apixaban [29] Edoxaban [27]
Anemia Contraindicated Contraindicated in patients with hemoglobin
<10 g/dL





Contraindicated in patients with hemoglobin <10 g/dL and patients with active pathologic bleeding
Can cause serious and sometimes fatal bleeding
Concomitant drugs affecting hemostasis can
increase bleeding risk, including platelet
aggregation inhibitors, heparin, fibrinolytic
therapy, and chronic use of NSAIDs
Concomitant drugs affecting hemostasis can
increase bleeding risk, including NSAIDs,
heparin, aspirin, platelet aggregation
inhibitors, other antithrombotic drugs, and
fibrinolytic therapy
Concomitant drugs affecting hemostasis can
increase bleeding risk, including platelet
aggregation inhibitors, other antithrombotic
drugs, heparin, thrombolytic agents, SSRIs,
SNRIs, and chronic use of NSAIDs
Concomitant use of drugs affecting
hemostasis may increase the risk of bleeding,
including aspirin and other antiplatelet agents,
other antithrombotic agents, fibrinolytic




To reduce risk of bleeding, discontinue
dabigatran 1–2 d (CrCl ≥50 mL/min) or 3–5
d (CrCl <50 mL/min) before invasive or
surgical procedures
To reduce risk of bleeding, discontinue
rivaroxaban at least 24 h prior to surgical or
other invasive procedures
To reduce risk of bleeding, discontinue
apixaban at least 48 h prior to elective
surgery or invasive procedures with a
moderate or high risk of unacceptable or
clinically significant bleeding, and at least
24 h prior to elective surgery or invasive
procedures with a low risk of bleeding or
where the bleeding would be noncritical in
location and easily controlled
To reduce the risk of bleeding, discontinue




Avoid concomitant use with P-gp inducers
(e.g., rifampin)
Avoid concomitant use with combined P-gp and
strong CYP3A4 inhibitors (e.g., ketoconazole, rito-
navir) or inducers (carbamazepine, pheny-
toin, rifampin, St. John’s wort)
Reduce apixaban dosage to 2.5 mg bid or
avoid concomitant use with strong dual
inhibitors of CYP3A4 and P-gp (e.g., ketocona-
zole, itraconazole, ritonavir, or clarithromycin)
Co-administration with anticoagulants,
antiplatelet drugs and thrombolytics may
increase the risk of bleeding
For patients with moderate renal impairment
(CrCl 30–50 mL/min), dabigatran dose may
be reduced to 75 mg bid when administered
concomitantly with the P-gp inhibitor drone-
darone or systemic ketoconazole. Dose adjust-
ment not required with P-gp inhibitors
(verapamil, amiodarone, quinidine, and
clarithromycin)
For patients with CrCl 15–50 mL/min,
rivaroxaban may be used concomitantly with
combined P-gp and weak or moderate
CYP3A4 inhibitors (e.g., amiodarone, diltiazem,
verapamil, quinidine, ranolazine, dronedarone,
felodipine, erythromycin, and azithromycin)
only if the potential benefit justifies the potential
risk
Avoid concomitant use with strong dual
inducers of CYP3A4 and P-gp (e.g., rifampin,
carbamazepine, phenytoin, St. John’s wort)
because such drugs will decrease exposure
to apixaban
Avoid concomitant use with rifampin
Avoid concomitant use with P-gp inhibitors
in patients with severe renal impairment
(CrCl 15–30 mL/min)
No dose reduction is recommended in
patients taking concomitant P-gp inhibitors
Hepatic
impairment
Large intersubject variability but no evident
consistent change in exposure or PD in
patients with moderate hepatic impairment
Avoid use in moderate and severe hepatic
impairment or with any hepatic disease
associated with coagulopathy
No dose adjustment necessary in patients
with mild hepatic impairment
Use of edoxaban in patients with moderate
or severe hepatic impairment is not
recommended as these patients may have
intrinsic coagulation abnormalities. No dose
reduction is required in patients with mild
hepatic impairment
No dosing recommendations available for
patients with moderate hepatic impairment
because of lack of clinical experience with
apixaban in these patients



















Table 5 Clinical and pharmacologic properties of apixaban, rivaroxaban, dabigatran, and edoxaban (Continued)
Renal
impairment
Contraindicated in patients with
CrCl <15 mL/min; reduce dosage to
75 mg bid if CrCl 15–30 mL/min
Avoid use in patients with CrCl <15 mL/min Reduce dosage to 2.5 mg bid in patients
with serum creatinine ≥1.5 mg/dL and either
age ≥80 years or body weight ≤60 kg
Reduce edoxaban dose to 30 mg qd in
patients with CrCl 15-50 mL/min. Not
recommended in patients with
CrCl<15 mL/min
5 mg bid in patients with ESRD maintained
on hemodialysis. Reduce dose to 2.5 mg bid
in patients with ESRD aged ≥80 years or
body weight ≤60 kg
Reversal
antidote




Dialysis [54] PCC (Cofact) [50] rFVIIa [51] rFVIIa [56]
aPCC (FEIBA®) [55] aPCC (FEIBA®) [53] aPCC (FEIBA®) [51] aPCC (FEIBA®) [56]
PER977 (when available) [76] Andexanet alfa (when available) [52] Activated charcoal [71] PPSB-HT [56]
PER977 (when available) [76] Andexanet alfa (when available) [49, 52]
PER977 (when available) [76]
aPCC activated prothrombin complex concentrate; bid twice dailym, CrCl creatinine clearance, CYP3A4 cytochrome P450 3A4, ESRD end-stage renal disease, FEIBA® factor VIII inhibitor bypass activity, NA not available,
NSAID nonsteroidal anti-inflammatory drug, PCC prothrombin complex concentrate, PD pharmacodynamics, P-gp P-glycoprotein, PPSB-HT prothrombin complex concentrate, rFVIIa recombinant activated factor VIIa,
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tion with warfarin or a NOAC (Table 2) [7, 8, 10, 11]. AS
has a history of GI bleeding with warfarin, and has several
characteristics associated with poor INR control including
his age, non-white race, and diabetes [59–61]. A NOAC
may provide a safer alternative to warfarin. However, in
the RE-LY and ROCKET-AF trials, dabigatran and rivarox-
aban, respectively, were associated with similar rates of
major bleeding and increased rates of GI bleeding versus
warfarin [23, 25]. In the RE-LY trial, the rates of major
bleeding for dabigatran 110 mg and 150 mg bid were
2.71 % per year (p = 0.003) and 3.11 % per year (p = 0.31),
respectively, compared with 3.36 % per year with warfarin
[23]. Rates of GI bleeding with dabigatran 110 mg and
150 mg versus warfarin were 1.12 % per year (p = 0.43)
and 1.50 % per year (p < 0.001) versus 1.02 % per year, re-
spectively [23]. Multiple GI bleeding events with dabiga-
tran have also been reported in recent postmarketing
surveillance [62]. In the ROCKET-AF trial, the rates of
major bleeding were 3.6 % per year and 3.4 % per year for
rivaroxaban and warfarin, respectively (p = 0.58), and GI
bleeding occurred in 3.2 % of patients with rivaroxaban
versus 2.2 % of patients with warfarin (p < 0.001) [25]. In
the ARISTOTLE trial comparing apixaban with warfarin,
apixaban demonstrated a 31 % reduction in major bleed-
ing and no increased risk of GI bleeding compared with
warfarin [24]. Non-bleeding GI adverse events (AEs) were
more common with dabigatran than with rivaroxaban in
the RE-LY and ROCKET-AF trials, respectively, versus
warfarin (16.9 % vs. 9.4 %; 5.33 % vs. 5.57 %, respectively)
[25, 63]. In the RE-LY trial, dyspepsia was the most com-
mon AE among patients receiving dabigatran, occurring
significantly more often with either dose of dabigatran
than with warfarin (p < 0.001 for both doses) [25]. An ana-
lysis of data from the RE-LY trial found that non-bleeding
upper GI AEs were generally mild or moderate with dabi-
gatran and warfarin [63]. However, patients receiving
dabigatran compared with warfarin were more likely to
discontinue the study drug due to non-bleeding upper GI
AEs or dyspepsia-like symptoms (4.0 % vs. 1.7 %; p <
0.001, respectively) [63]. Similar findings were not ob-
served for apixaban or rivaroxaban in the ARISTOTLE
and ROCKET-AF trials, respectively [24, 25]. In the
ROCKET-AF trial, the only difference in incidence of AEs
between treatment groups was epistaxis, which occurred
more frequently in patients receiving rivaroxaban than pa-
tients receiving warfarin (10.14 % vs. 8.55 %, p < 0.05) [25].
In the ARISTOTLE trial, the incidence of AEs was similar
in the treatment groups [24].
AS’s comorbidities and concomitant medications
should also be considered when selecting a NOAC. Hav-
ing diabetes places AS at increased risk of bleeding when
taking oral anticoagulants, and also poses the possibility of
renal impairment [28, 64, 65]. Of the 3 NOACs, apixabanhas the least renal elimination (~27 %) compared with
rivaroxaban (~36 %) and dabigatran (~80 %), and is also
eliminated via biliary and possibly direct intestinal excretion
(Table 5) [27–29, 64–71]. Apixaban also demonstrated su-
periority over warfarin in reducing risk of stroke/SE, major
bleeding, and mortality, irrespective of renal function [72].
Apixaban 5 mg twice daily may be a good NOAC option
for this patient who is at high risk of bleeding and with
comorbidities [7, 8, 10].
Discussion and conclusions
Conventional treatment options for reducing the risk of
stroke in patients with NVAF, including VKAs and aspirin,
have limitations that currently leave many patients under-
treated or untreated, and thus, suboptimally protected from
stroke. The NOACs provide an additional treatment path-
way that may help address this trend by offering treatment
options with equivalent or improved efficacy and safety
compared with warfarin. Current treatment guidelines
have begun to incorporate recommendations for use of
the available NOACs, and as additional data emerge and
guidelines are further updated, these recommendations
will likely evolve. In the interim, clinicians may need to
consider the recommendations of published guidelines
while also weighing results of clinical trials on NOACs.
Furthermore, real-world experience will provide clinicians
with additional insight into their treatment decisions. The
challenge, however, will be for clinicians to assess the
benefits and risks of treatment within the framework of
the individual characteristics that define each patient
case scenario. Use of scoring systems to assess stroke
and bleeding risk; consideration of patient characteristics
such as concomitant medications, age, and renal failure;
and an understanding of relevant pharmacologic charac-
teristics of the NOACs will all assist in these treatment
decisions (Table 5).
When comparing the results of clinical trials of each
NOAC versus warfarin, subtle differences in clinical out-
comes become evident, such as rates of stroke, SE, all-cause
mortality, major bleeding, and intracranial hemorrhage. For
example, compared with warfarin, dabigatran 150 mg pro-
vided greater risk reduction for stroke and SE in the RE-LY
trial than did apixaban, rivaroxaban, or edoxaban in the
ARISTOTLE, ROCKET-AF, and ENGAGE AF-TIMI 48
trials, respectively (Table 1) [23–28]. However, edoxaban
and apixaban had a greater risk reduction for major bleed-
ing versus warfarin than did dabigatran, as well as greater
risk reduction for stroke and SE versus warfarin than did
rivaroxaban. Apixaban and dabigatran 150 mg had a similar
risk reduction for intracranial hemorrhage, but less than
edoxaban 30 mg and dabigatran 110 mg and more than
rivaroxaban. Rivaroxaban, apixaban, dabigatran 150 mg,
and edoxaban provided comparable risk reduction versus
warfarin for all-cause mortality [23–28]. Three formal
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ROCKET-AF trials confirm these observations with re-
gard to rivaroxaban, apixaban, and dabigatran [73–75].
One study quantified the benefits and risks of the NOACs
with the following odds ratios (ORs) for stroke or SE: riv-
aroxaban versus dabigatran 150 mg, OR, 1.35 (p = 0.04);
rivaroxaban versus dabigatran 110 mg, OR, 0.97 (p = 0.81);
apixaban versus dabigatran 150 mg, OR, 1.22 (p = 0.18);
apixaban versus dabigatran 110 mg, OR, 0.88 (p = 0.34);
apixaban versus rivaroxaban, OR, 0.90 (p = 0.43). For
major bleeding, the estimated ORs were: rivaroxaban ver-
sus dabigatran 150 mg, OR, 1.10 (p = 0.36); rivaroxaban
versus dabigatran 110 mg, OR, 1.28 (p = 0.02); apixaban
versus dabigatran 150 mg, OR, 0.74 (p = 0.004); apixaban
versus dabigatran 110 mg, OR, 0.87 (p = 0.17); apixaban
versus rivaroxaban, OR, 0.68 (p < 0.001) [74]. Indirect
comparisons like these must be considered with cau-
tion because of differences in trial design and patient
populations.
With the availability of the NOACs, success in reducing
the risk of stroke among patients with NVAF no longer
has to pivot on the suitability of warfarin for patients.
Until treatment guidelines are updated to incorporate all
available data on the NOACs, clinicians would be well ad-
vised to consider recent clinical trial data for these agents
alongside current treatment guidelines for stroke preven-
tion in AF. Such attentiveness may help render treatment
decisions that accurately address the constellation of char-
acteristics composing each individual case and result in
safe, high-quality, and cost-effective patient care.
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